Global Expansion Series: Australia market entry and operations setup
The Australian market presents an exceptional environment by offering access to world-class scientific talent and cutting-edge expertise. Renowned contract research and manufacturing organisations adhere to Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) guidelines, ensuring that R&D activities meet the highest quality standards. Additionally, Australia boasts strong clinical trial capabilities and an efficient ethics and regulatory framework — where no IND or GMP-manufactured product is required for Phase 1 trials — providing a streamlined pathway for innovation. This interconnected ecosystem and the generous R&D tax incentives and grants available, make Australia an increasingly attractive destination for advancing biotech and pharmaceutical research.
Given these advantages, we are seeing an increasing number of enterprises, particularly from Mainland China and Hong Kong, looking to enter the Australian market. To equip these companies with the knowledge needed to expand their operations in Australia, Vistra hosted a webinar aimed at exploring the opportunities available, especially for biotech and pharmaceutical companies. We will also discuss important considerations for operating in Australia.
Key highlights of the seminar:
1. Overview of Australia opportunities for Chinese and Hong Kong biotech and pharmaceutical companies
- Insights into the Australian market landscape and potential growth areas.
- Key trends and demand in the biotech and pharmaceutical sectors.
2. Updates on the Australian biotech landscape
- Overview of regulatory requirements for biotech and pharmaceutical companies entering Australia.
- Insights into the Therapeutic Goods Administration (TGA) processes.
3. Review of Vistra’s capability in Australia in support of biotech
- Hints and tips for frictionless entry into Australia
4. Tax incentives for biotech and pharmaceutical companies
- Exploration of tax incentives and government grants available in Australia
- Exploration of the criteria for accessing the above tax incentives – core and supporting R&D activities, and clinical trials determination
5. Key considerations for qualifying for the incentives
- Key considerations (i.e. IP ownership, tax structuring, transfer pricing arrangements, Foreign-owned vs Australian-owned R&D), including issues related to tax treaties with Hong Kong and Mainland China.
- The opportunities await your organisation
Fill out the form to watch the on-demand:
The contents of this article are intended for informational purposes only. The article should not be relied on as legal or other professional advice. Neither Vistra Group Holding S.A. nor any of its group companies, subsidiaries or affiliates accept responsibility for any loss occasioned by actions taken or refrained from as a result of reading or otherwise consuming this article. For details, read our Legal and Regulatory notice at: https://www.vistra.com/notices . Copyright © 2026 by Vistra Group Holdings SA. All Rights Reserved.
